Somewhat Favorable News Coverage Somewhat Unlikely to Impact Fluidigm (FLDM) Share Price
News headlines about Fluidigm (NASDAQ:FLDM) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fluidigm earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.1391665677629 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Fluidigm (NASDAQ:FLDM) traded down $0.19 during midday trading on Monday, hitting $6.53. The stock had a trading volume of 168,600 shares, compared to its average volume of 239,525. Fluidigm has a twelve month low of $2.52 and a twelve month high of $8.69. The stock has a market capitalization of $245.41, a P/E ratio of -2.93 and a beta of 3.37. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02.
Separately, ValuEngine downgraded Fluidigm from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Stock Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related stocks with our FREE daily email newsletter.